# A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

> **NCT04993690** · PHASE1 · RECRUITING · sponsor: **Guangzhou Lupeng Pharmaceutical Company LTD.** · enrollment: 200 (estimated)

## Conditions studied

- B-cell Lymphoma

## Interventions

- **DRUG:** LP-168 tablet

## Key facts

- **NCT ID:** NCT04993690
- **Lead sponsor:** Guangzhou Lupeng Pharmaceutical Company LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-06
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04993690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04993690, "A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04993690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*